Company: DERM
Filing Date: 2025-08-28
Form Type: 424B3
Source: 0001104659-25-084876
Chunk: 7

Company: Journey Medical Corp
Filing Date: 2025-08-28
Form: 424B3
Chunk 7
---
 (the “JOBS Act”), and may remain an emerging
growth company until December 31, 2026, or until such earlier time as we have more than $1.235 billion in annual revenue, we become
a “large accelerated filer” under SEC rules, or we issue more than $1 billion of non-convertible debt over a three-year
period. The JOBS Act contains provisions that, among other things, reduce certain reporting requirements for an “emerging
growth company.” For so long as we remain an emerging growth company, we are permitted and plan to rely on exemptions from certain
disclosure requirements that are applicable to other public companies that are not emerging growth companies.

These exemptions include
reduced disclosure obligations regarding executive compensation. In addition, as an emerging growth company, we are not required to conduct
votes seeking approval, on an advisory basis, of the compensation of our named executive officers or the frequency with which such votes
must be conducted. We may take advantage of some or all of these exemptions until such time as we are no longer an emerging growth company.

We are also a “smaller
reporting company,” meaning that the market value of our stock held by non-affiliates is less than $700 million and our
annual revenue was less than $100 million during the most recently completed fiscal year. We may continue to be a smaller reporting company
if either (i) the market value of our stock held by non-affiliates is less than $250 million or (ii) our annual revenue
was less than $100 million during the most recently completed fiscal year and the market value of our stock held by non-affiliates was
less than $700 million. If we are a smaller reporting company at the time we cease to be an emerging growth company, we may continue to
rely on exemptions from certain disclosure requirements that are available to smaller reporting companies. For so long as we remain a
smaller reporting company, we are permitted and intend to rely on exemptions from certain disclosure and other requirements that are applicable
to other public companies that are not applicable to a smaller reporting company.

<div align='center'>S-4</div>

THE OFFERING

| Common Stock Offered By Us                         | Up to 3,750,000 shares of our common stock.                                                                                                                                                                                                                                                                                                                                                          |
| Common Stock to be Outstanding After This Offering | Up                                                                                                                                                                                                                                                                                                                                                                                                   
 to 30,059,844 shares, assuming sales of all 3,750